Skip to main content

Table 1 Clinicopathologic variables and univariate analysis of the Chinese training cohort and SEER external validation cohort of gastric cancer patients

From: Proposal and validation of a modified staging system to improve the prognosis predictive performance of the 8th AJCC/UICC pTNM staging system for gastric adenocarcinoma: a multicenter study with external validation

Variable

Training cohort (n = 7911)

External validation cohort (n = 10,208)

No. of patients [cases (%)]

5-year OS rate (%)

P value

No. of patients [cases (%)]

5-year OS rate (%)

P value

Age (years)

< 0.001

  

< 0.001

 ≤ 59

4117 (52.0)

57.6

 

5142 (50.4)

47.1

 

 > 59

3794 (48.0)

48.0

 

5066 (49.6)

34.9

 

Gender

0.108

  

0.082

 Male

5586 (70.6)

52.5

 

6360 (62.3)

40.1

 

 Female

2325 (29.4)

54.3

 

3848 (37.7)

42.3

 

Tumor location

< 0.001

  

< 0.001

 Antrum

3578 (45.2)

61.4

 

3382 (33.1)

43.2

 

 Body

1523 (19.3)

50.5

 

2701 (26.5)

47.2

 

 Cardia/fundus

2144 (27.1)

47.7

 

3694 (36.2)

36.9

 

 Whole stomach

666 (8.4)

30.7

 

431 (4.2)

19.1

 

Tumor size (cm)

< 0.001

  

< 0.001

 ≤ 4.5

4081 (51.6)

65.5

 

5086 (49.8)

51.4

 

 > 4.5

3830 (48.4)

39.9

 

5122 (50.2)

31.1

 

Lauren type

< 0.001

  

< 0.001

 Intestinal

3329 (42.1)

59.7

 

4062 (39.8)

47.7

 

 Diffuse

4582 (57.9)

48.2

 

6146 (60.2)

36.6

 

pT stage

< 0.001

  

< 0.001

 T1

954 (12.1)

95.6

 

2172 (21.3)

72.3

 

 T2

1447 (18.3)

66.4

 

1402 (13.7)

55.0

 

 T3

1291 (16.3)

53.2

 

3901 (38.2)

33.4

 

 T4a

3675 (46.5)

40.6

 

2061 (20.2)

22.5

 

 T4b

544 (6.9)

26.8

 

672 (6.6)

18.4

 

pN stage

< 0.001

  

< 0.001

 N0

2870 (36.3)

79.6

 

4014 (39.3)

62.3

 

 N1

1403 (17.7)

57.6

 

2069 (20.3)

40.4

 

 N2

1547 (19.6)

44.0

 

1849 (18.1)

30.0

 

 N3a

1407 (17.8)

24.2

 

1654 (16.2)

16.4

 

 N3b

684 (8.6)

14.1

 

622 (6.1)

8.9

 

pTNM stage (7th ed.)

< 0.001

  

< 0.001

 IA

801 (10.1)

96.6

 

1718 (16.8)

76.6

 

 IB

735 (9.3)

84.4

 

1048 (10.3)

62.5

 

 IIA

699 (8.8)

75.5

 

1507 (14.8)

51.3

 

 IIB

1499 (18.9)

63.0

 

1512 (14.8)

38.1

 

 IIIA

1248 (15.8)

46.6

 

1410 (13.8)

29.6

 

 IIIB

1352 (17.1)

35.8

 

1777 (17.4)

20.9

 

 IIIC

1577 (19.9)

17.4

 

1236 (12.1)

10.9

 

pTNM stage (8th ed.)

< 0.001

  

< 0.001

 IA

801 (10.1)

96.6

 

1718 (16.8)

76.6

 

 IB

735 (9.3)

84.4

 

1048 (10.3)

62.5

 

 IIA

699 (8.8)

75.5

 

1507 (14.8)

51.3

 

 IIB

1499 (18.9)

63.0

 

1507 (14.8)

38.2

 

 IIIA

2076 (26.2)

44.5

 

2012 (19.7)

28.5

 

 IIIB

1340 (16.9)

23.2

 

1643 (16.1)

16.9

 

 IIIC

761 (9.6)

13.6

 

773 (7.6)

8.1

 

pTNM stage (modified)

< 0.001

  

< 0.001

 IA

801 (10.1)

96.6

 

1718 (16.8)

76.6

 

 IB

735 (9.3)

84.4

 

1048 (10.3)

62.5

 

 IIA

699 (8.8)

75.5

 

1507 (14.8)

51.3

 

 IIB

1499 (18.9)

63.0

 

1507 (14.8)

38.2

 

 IIIA

1078 (13.6)

50.9

 

1420 (13.9)

30.3

 

 IIIB

1447 (18.3)

36.9

 

1668 (16.3)

21.7

 

 IIIC

1652 (20.9)

16.0

 

1340 (13.1)

9.7

 
  1. p pathological, TNM tumor-node-metastasis, ed. edition